DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa

Information source: Massachusetts General Hospital
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Anorexia Nervosa; Osteoporosis

Intervention: estradiol 0.045 mg/levonorgestrel 0.015mg (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Massachusetts General Hospital

Overall contact:
Pouneh K. Fazeli, MD, Phone: 617-726-1347, Email: pkfazeli@partners.org

Summary

Decreased bone strength is a common and serious medical problem present in many women with anorexia nervosa. Women with decreased bone strength are more likely to suffer broken bones than women with normal bone strength. This study will investigate whether the use of transdermal estrogen can improve bone mineral density (BMD) and bone microarchitecture in women with anorexia nervosa anorexia nervosa when used for 6 months.

Clinical Details

Official title: Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Bone mineral density (BMD) of lumbar spine by dual energy x-ray absorptiometry (DXA)

Secondary outcome: Bone microarchitecture of the distal radius and tibia by high-resolution peripheral quantitative computed tomography (HR-pQCT)

Detailed description: Anorexia nervosa (AN) is a prevalent psychiatric disorder affecting up to 1% of college-aged women in the US and an increasing number of women over 30 years of age. Among the many medical co-morbidities associated with AN, the most common is significant bone loss, which can persist despite weight recovery. Nearly 50% of women with AN have osteopenia with an additional 30% meeting WHO criteria for osteoporosis. Importantly, this severe bone loss is associated with an increased fracture risk. Nearly 30% of women with AN report a history of a fracture and a prospective study demonstrated a 7-fold increased risk of fracture in women with AN compared to age-matched controls. Because AN is a chronic disease that can persist despite psychiatric and nutritional counseling, the bone loss and increased fracture risk can persist and lead to lifelong morbidity. Therefore, finding a treatment for bone loss associated with AN is of critical importance. This 6 month open-label study will investigate in women (ages 30 to 50 years old) with AN whether treatment with transdermal estrogen replacement will increase bone mineral density (BMD), improve parameters of bone microarchitecture as assessed by high-resolution peripheral quantitative computed tomography (HR-pQCT), and improve bone strength as estimated by microfinite element analysis.

Eligibility

Minimum age: 30 Years. Maximum age: 50 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Female; ages 30-50 years

- Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V)

psychiatric criteria for AN, including <85% of ideal body weight as defined by the 1983 Metropolitan Life Insurance Height and Weight Tables, and amenorrhea

- T-score of < -1. 5 at spine or hip

- Treatment team or treatment professional in place for clinical treatment/monitoring

during the study Exclusion Criteria:

- Diseases known to affect bone metabolism, including untreated thyroid dysfunction,

vitamin D deficiency, Cushing's syndrome, diabetes mellitus or renal insufficiency

- Personal history of venous or arterial clot

- History of stroke or myocardial infarction

- History of migraine headaches

- History of hypercoagulable disorder

- Personal history or history of a first-degree relative with breast cancer

- History of hereditary angioedema

- Any medication known to affect bone metabolism, including systemic glucocorticoids

within three months of the baseline visit, depot medroxyprogesterone within 6 months of the baseline visit, oral bisphosphonates within one year of the baseline visit or intravenous (IV) bisphosphonates within three years of the baseline visit

- Bone fracture within the prior 12 months

- Serum potassium < 3. 0 meq/L or serum alanine aminotransferase (ALT) > 3 times the

upper limit of normal

- Fasting serum triglyceride level > 150 mg/dL

- Pregnant or breastfeeding

- Active substance abuse

Locations and Contacts

Pouneh K. Fazeli, MD, Phone: 617-726-1347, Email: pkfazeli@partners.org

Massachusetts General Hospital, Boston, Massachusetts 02114, United States; Recruiting
Pouneh K Fazeli, MD, Phone: 617-726-3870, Email: pkfazeli@partners.org
Pouneh K Fazeli, MD, Principal Investigator
Additional Information

Starting date: June 2015
Last updated: June 15, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017